Tags : Bridge Biotherapeutics

Top 20

Top 20 Biopharma Deal Terminations of 2020 Based on Total

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi’s agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology, lapscovery. The second position goes to the […]Read More


Bridge Biotherapeutics Signs a License Agreement with Konkuk University for

Shots: Konkuk University to receive $0.25M upfront, ~$8.1M development and commercial milestones while Bridge Biotherapeutics to get WW exclusive license for the compound and will lead preclinical and development process of the therapy Additionally, in 2019, Bridge Biotherapeutics signed a license agreement with Boehringer Ingelheim to develop BBT-877, an autotaxin inhibitor targeting fibrosing interstitial lung […]Read More


Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics

Shots: Bridge to receive $50.66M as up front and near-term payments, up to $1.23B based on development, regulatory, and commercial milestones and royalties on sales The focus of the collaboration is to develop Bridge’s BBT-877 candidate and expand BI’s pipeline of fibrosing interstitial lung diseases in developing therapies for patients with Idiopathic Pulmonary Fibrosis (IPF)  […]Read More